Triamterene And Hydrochlorothiazide
NDC Package 70934-159-30
Package Information
Triamterene And Hydrochlorothiazide is this fixed combination drug is not indicated for the initial therapy of edema or hypertension except in individuals in whom the development of hypokalemia cannot be risked.Triamterene and hydrochlorothiazide tablets are indicated for the treatment of hypertension or edema in patients who develop hypokalemia on hydrochlorothiazide alone. Marketed by Denton Pharma, Inc. Dba Northwind Pharmaceuticals, this product is identified by NDC 70934-159 and is authorized under FDA application ANDA073449.
Identification & Billing
- RxCUI: 310812 - triamterene 37.5 MG / hydroCHLOROthiazide 25 MG Oral Tablet
- RxCUI: 310812 - hydrochlorothiazide 25 MG / triamterene 37.5 MG Oral Tablet
- RxCUI: 310812 - HCTZ 25 MG / triamterene 37.5 MG Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 70934 - Denton Pharma, Inc. Dba Northwind Pharmaceuticals
- 70934-159 - Triamterene And Hydrochlorothiazide
- 70934-159-30 - 30 TABLET in 1 BOTTLE, PLASTIC
- 70934-159 - Triamterene And Hydrochlorothiazide
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 70934-159-30 identifies a specific commercial package of 30 tablet in 1 bottle, plastic of Triamterene And Hydrochlorothiazide, labeled by Denton Pharma, Inc. Dba Northwind Pharmaceuticals. This product is billed for "EA" each discreet unit and contains an estimated amount of 30 billable units per package. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Denton Pharma, Inc. Dba Northwind Pharmaceuticals on August 28, 2018. The current certification is valid through December 31, 2022.
How is this Denton Pharma, Inc. Dba Northwind Pharmaceuticals product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 70934015930. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.